Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease

  1. Kejia Zhang
  2. Patrick Eldin
  3. Jessica H Ciesla
  4. Laurence Briant
  5. Jenna M Lentini
  6. Jillian Ramos
  7. Justin Cobb
  8. Joshua Munger
  9. Dragony Fu  Is a corresponding author
  1. Department of Biology, Center for RNA Biology, University of Rochester, United States
  2. Institut de Recherche en Infectiologie de Montpellier (IRIM), CNRS, UMR 9004, Université de Montpellier, France
  3. Department of Biochemistry and Biophysics, University of Rochester Medical Center, United States
8 figures, 1 table and 1 additional file

Figures

Figure 1 with 1 supplement
Human cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a reduction in tRNA methyltransferase 1 (TRMT1) levels and perturbations in tRNA modification patterns.

(A) Immunoblot analysis of lysates prepared from MRC-5-ACE2 human cells that were mock-infected or infected with SARS-CoV-2 at multiplicity of infection (MOI) of 5 for 24 or 48 hr. The immunoblot was probed with anti-TRMT1, actin, or SARS-CoV-2 nucleocapsid (N) antibodies. Circle represents endogenous full-length TRMT1. Asterisk (*) denotes a non-specific band. Size markers are noted in kiloDalton. (B) Quantification of TRMT1 signal intensity normalized to actin in the mock or SARS-CoV-2-infected cell lines. TRMT1 protein levels are expressed relative to mock-infected samples for each time point. (C) m2,2G levels in small RNAs isolated from MRC5 cells that were either mock-infected or infected with SARS-CoV-2 at MOI of 5 for 24 or 48 hr. m2,2G levels were normalized to A, C, G, and U. Samples were measured in biological replicates. Statistical significance for (B) and (C) was determined by two-way ANOVA with multiple comparisons test. ***p<0.001; ****p<0.0001; ns, non-significant. (D) Levels of the indicated RNA modifications in small RNAs isolated from MRC5 cells that were either mock-infected or infected with SARS-CoV-2 for 24 or 48 hr. RNA modification levels were normalized to A, C, G, and U. Y-axis represents the log2 fold change in the levels of the indicated tRNA modification between SARS-CoV-2 infected versus mock-infected MRC5 cells. The experiment in (C) was repeated as an independent biological replicate in Figure 1—figure supplement 1.

Figure 1—figure supplement 1
LC-MS analysis of dimethylguanosine (m2,2G) levels in small RNAs isolated from MRC5 cells that were either mock-infected or infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at multiplicity of infection (MOI) of 5 for 24 or 48 hr.

m2,2G levels were normalized to guanosine. Samples were measured in biological replicates. Statistical significance was determined by two-way ANOVA with multiple comparisons test. *p<0.05; ns, non-significant.

Figure 1—figure supplement 1—source data 1

LC-MS measurements of RNA modifications.

https://cdn.elifesciences.org/articles/90316/elife-90316-fig1-figsupp1-data1-v1.xls
Figure 2 with 1 supplement
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein 5 (Nsp5) binds tRNA methyltransferase 1 (TRMT1) in human cells.

(A) Schematic of human TRMT1 primary structure with predicted Nsp5 cleavage site. Mitochondrial targeting signal (MTS), methyltransferase (MT) domain, and zinc finger motif are denoted. (B) Consensus sequence logo of cleavage sites in SARS-CoV-2 polyproteins. (C) Alpha-fold predicted structure of human TRMT1 with putative Nsp5 cleavage site denoted in magenta and arrowhead. (D) Immunoblot of input and strep-tactin purifications from human cells expressing empty vector, wild-type (WT) Nsp5, or Nsp5-C145A fused to the Strep-tag without or with co-expression with TRMT1-FLAG. The immunoblot was probed with anti-Strep, FLAG, and actin antibodies. Square represents TRMT1-FLAG, circle represents endogenous TRMT1. Size markers are noted to the left in kiloDalton. The experiment in (D) was repeated as an independent biological replicate in Figure 2—figure supplement 1.

Figure 2—figure supplement 1
Immunoblot of input and strep-tactin purifications from human cells expressing empty vector, wild-type (WT) nonstructural protein 5 (Nsp5), or Nsp5-C145A fused to the Strep-tag without or with co-expression with tRNA methyltransferase 1 (TRMT1)-FLAG.

The immunoblot was probed with anti-TRMT1, Strep, or actin antibodies. Circle represents endogenous TRMT1.

Nonstructural protein 5 (Nsp5) expression induces cleavage of tRNA methyltransferase 1 (TRMT1) in human cells.

(A) Immunoblot of lysates prepared from human 293T cells expressing GFP, Nsp5 or Nsp5-C145A. The immunoblot was probed with anti-TRMT1, Strep, or actin antibodies. Hours post represents the time post-transfection. Circle represents endogenous TRMT1. Arrow represents the N-terminal (N)-TRMT1 cleavage fragment. Asterisk (*) denotes a non-specific band. Size markers to the left in kiloDalton. (B, C) Quantification of endogenous TRMT1 or N-terminal (N)-TRMT1 cleavage product in transfected cells. TRMT1 and N-TRMT1 signal was normalized to actin. (D) Immunoblot of lysates prepared from wild-type or TRMT1-knockout (KO) human cell lines expressing Nsp5. Experiments in (A) and (D) were repeated three times in biological replicates (see source data).

Figure 4 with 1 supplement
Sequence-dependent cleavage of tRNA methyltransferase 1 (TRMT1) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein 5 (Nsp5).

(A) Immunoblot of lysates from human cells expressing empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep without or with co-expression with TRMT1-FLAG. The immunoblot was probed with anti-Strep, FLAG, and actin antibodies. Square represents TRMT1-FLAG, Asterisk (*) denotes a non-specific band, arrow represents N-terminal TRMT1 cleavage product and arrowhead indicates the C-terminal TRMT1 cleavage product. (B) Schematic of human TRMT1 with predicted Nsp5 cleavage site and Q530N mutation. (C) Immunoblot of lysates from human cells expressing empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep without or with co-expression with TRMT1-FLAG or TRMT1-FLAG Q530N. Experiments in (A) and (C) were repeated three times as biological replicates with comparable results (see source data).

Figure 4—figure supplement 1
Detection of the C-terminal tRNA methyltransferase 1 (TRMT1) fragment produced by nonstructural protein 5 (Nsp5)-dependent cleavage in human cells.

(A) Immunoblot of lysates from the indicated wild-type (WT) or TRMT1-knockout (K)O human 293T cells that were untransfected (-) (lanes 1 and 2) or transfected with empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep expression plasmids (lanes 3 through 5). The blot was probed with an antibody detecting residues 609–659 of TRMT1. Circle represents endogenous TRMT1. (B) Immunoblot of lysates from human cells that were transfected with TRMT1-FLAG or TRMT1-FLAG Q530N expression plasmids along with empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep expression plasmids. The blot was probed with an antibody detecting residues 609–659 of TRMT1. Circle represents endogenous TRMT1, square represents TRMT1-FLAG, and arrowhead indicates the C-terminal TRMT1 cleavage product. Asterisks (*) denote bands that are still detectable in the TRMT1-KO cell line. The band at ~35 kDa in lanes 3 and 6 of (B) represents non-specific detection of the Nsp5-C145A variant that exhibits extremely high levels of expression since it cannot self-cleave.

Figure 5 with 1 supplement
N- and C-terminal tRNA methyltransferase 1 (TRMT1) cleavage fragments exhibit alterations in RNA binding and tRNA modification activity.

(A) Schematic of wild-type TRMT1 and predicted TRMT1 fragments resulting from nonstructural protein 5 (Nsp5) cleavage at Q530N. (B) Immunoblot analysis of anti-FLAG purifications from human cells expressing vector control, full-length TRMT1, or TRMT1 cleavage fragments fused to the FLAG tag. The immunoblot was probed with anti-FLAG and anti-actin antibodies. (C) Nucleic acid stain of RNAs extracted from the indicated input or purified samples after denaturing PAGE. The migration pattern of 5.8 S rRNA (~150 nt), 5 S rRNA (~120 nt), and tRNAs (~70–80 nt) are denoted. (D) Immunoblot of TRMT1 expression in either control-wild-type (WT) or TRMT1-knockout (KO) human 293T cell lines. (E, F) Representative gel of primer extension assays to monitor the presence of dimethylguanosine (m2,2G) in tRNA-Met-CAU or mt-tRNA-Ile-GAU from the cell lines transfected with the indicated TRMT1 constructs. D, dihydrouridine; m1G, 1-methylguanosine; >, labeled oligonucleotide used for primer extension. Protein-RNA purification was repeated with comparable results (see source data for repeat).

Figure 5—figure supplement 1
Confocal microscopy images of 293T cells transiently transfected with constructs expressing tRNA methyltransferase 1 (TRMT1) or TRMT1 fragments fused with green fluorescent protein (GFP).

Mitochondria were identified using mitochondrion-targeted red fluorescent protein (Mito-RFP) and nuclear DNA was stained with Hoechst. Overlap of red mitochondria and green GFP signal is displayed in the Merge panels.

Figure 6 with 1 supplement
The expression of tRNA methyltransferase 1 (TRMT1) affects the levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA replication in human cells.

(A) Immunoblot of lysates prepared from 293T control-wild-type (WT) or TRMT1-knockout (KO) cell lines that were mock-infected (multiplicity of infection, MOI of 0) or infected with SARS-CoV-2 at MOI of 0.2 or 0.4 for 24 hr. The immunoblot was probed with antibodies against TRMT1 or actin. Circle represents endogenous full-length TRMT1. Asterisk (*) denotes a non-specific band. Size markers to the right in kiloDalton. (B) Normalized TRMT1 signal intensity relative to mock-infected cells (MOI of 0). Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons test. (C) Immunoblot of lysates prepared from 293T control-wild-type (WT) or TRMT1-KO cell lines that were mock-infected (MOI of 0) or infected with SARS-CoV-2 at MOI of 0.1 or 5.0 for 24 hr. The immunoblot was probed with antibodies as in (A). (D) Normalized TRMT1 signal intensity relative to mock-infected cells (MOI of 0). (E, F) SARS-CoV-2 RNA copy number in control-WT or TRMT1-KO human 293T cell lines after infection at the indicated MOI for 24 hr. Viral copy number was measured by QRT-PCR and normalized to GAPDH. Samples were measured in triplicate. Statistical significance was determined by two-way ANOVA with Šídák’s multiple comparisons test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, non-significant.

Figure 6—source data 1

Raw uncropped immunoblots for Figure 6.

https://cdn.elifesciences.org/articles/90316/elife-90316-fig6-data1-v1.zip
Figure 6—source data 2

QRT-PCR measurements of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA.

https://cdn.elifesciences.org/articles/90316/elife-90316-fig6-data2-v1.xlsx
Figure 6—figure supplement 1
Human 293T cell lines expressing ACE2 can be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

(A) Immunoblot analysis of lysates prepared from the indicated 293T cell lines expressing empty vector or ACE2. The immunoblot was probed with anti-ACE2 and actin. (B) Immunoblot analysis of lysates prepared from 293T-ACE2 cell lines that were mock-infected (multiplicity of infection, MOI 0) or infected with SARS-CoV-2 at the indicated MOI. The blot was probed against the SARS-CoV-2 nucleocapsid (N) and actin.

Figure 7 with 2 supplements
tRNA methyltransferase 1 (TRMT1) is required for efficient severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in human cells.

(A) Immunoblot of lysates prepared from the indicated 293T TRMT1-knockout (KO) cell lines that were mock-infected (multiplicity of infection, MOI of 0) or infected with SARS-CoV-2 for 24 hr. The immunoblot was probed with antibodies against TRMT1 or actin. Square represents full-length TRMT1-FLAG. Asterisk (*) denotes a non-specific band. Size markers to the left in kiloDalton. (B) Normalized TRMT1-WT signal intensity relative to mock-infected cells (MOI of 0). (C) Normalized TRMT1-Q530N signal intensity relative to mock-infected cells (MOI of 0). Statistical significance was determined in (B) and (C) by one-way ANOVA with Dunnett’s multiple comparisons test. (D) SARS-CoV-2 RNA copy number in control-wild-type (WT) or TRMT1-KO human 293T cell lines after infection at the indicated MOI. Viral copy number was measured by QRT-PCR and normalized to GAPDH. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test. *p<0.05; **p<0.01; ****p<0.0001; ns, non-significant.

Figure 7—source data 1

Raw uncropped immunoblots for Figure 7A.

https://cdn.elifesciences.org/articles/90316/elife-90316-fig7-data1-v1.zip
Figure 7—source data 2

QRT-PCR measurements of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA for Figure 7D.

https://cdn.elifesciences.org/articles/90316/elife-90316-fig7-data2-v1.xlsx
Figure 7—figure supplement 1
Expression of nonstructural protein 5 (Nsp5) leads to cleavage of tRNA methyltransferase 1 (TRMT1)-wild-type (WT) re-expressed in TRMT1-knockout (KO) cells, but not TRMT1-Q530N.

Immunoblot of lysates from human cells integrated with empty lentiviral vector or lentiviral expression vectors for wild-type (WT) TRMT1 or TRMT1-Q530N. The cell lines were transfected with either a vector or a construct expressing Nsp5-Strep. The immunoblot was probed with anti-TRMT1, Strep, and actin antibodies. Square represents TRMT1-FLAG, circle represent endogenous TRMT1, Asterisk (*) denotes a non-specific band, and arrow represents N-terminal TRMT1 cleavage product.

Figure 7—figure supplement 2
Immunoblot analysis of lysates prepared from the indicated 293T cell lines expressing empty vector or ACE2.

The immunoblot was probed with anti-ACE2 and actin.

Viral infectivity measurement of supernatants collected from the indicated cell lines infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for 24 hr.

(A) Viral titer of supernatants collected from the indicated cell lines infected with SARS-CoV-2. Infectious titer was determined by TCID50 endpoint dilution assay in VeroE6 cells and expressed in focus forming units per mL of supernatant (FFU/mL). (B) Infectivity of SARS-CoV-2 particles generated from cell lines in (A). Infectivity of viral particles was calculated with the formula [(FFU/mL)/(viral genomic RNA copies/mL)], and expressed in FFU per 100 genomic copies.

Figure 8—source data 1

Infectious titers and QRT-PCR results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

https://cdn.elifesciences.org/articles/90316/elife-90316-fig8-data1-v1.xlsx

Tables

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Cell line (Homo sapiens, female)293TATCCATCC: CRL-3216
Cell line (Homo sapiens, male)MRC5 +ACE2Raymonda et al., 2022ATCC: CCL-171
Strain (coronavirus)SARS-CoV-2BEI resourcesNR-52282Isolate Hong Kong/VM20001061/2020
Strain (coronavirus)SARS-CoV-2European Virus Archive014 V-03890Isolate BetaCoV/France/
IDF0372/2020
Commercial assay or kitRNA Clean & Concentrator-5 kitZymoR1013
Software, algorithmGraphPad PrismDotmaticsPrism 10, version 10.2.2 (341)
Software, algorithmChimeraPettersen et al., 2004X-1.6.1
Gene (Homo sapiens)TRMT1GenBankGene ID: 55621
Recombinant DNA reagent (plasmid)pcDNA3.1-TRMT1-FLAGDewe et al., 2017Fu Lab plasmid, mammalian expression vector for wild-type TRMT1 fused to FLAG
Recombinant DNA reagent (plasmid)pcDNA3.1-TRMT1-GFPDewe et al., 2017Fu Lab plasmid, mammalian expression vector for wild-type TRMT1 fused to GFP
Recombinant DNA reagent (plasmid)pcDNA3.1-TRMT1-FLAG-Q530NThis paperFu Lab plasmid, mammalian expression vector for TRMT1-Q530N variant fused to FLAG
Recombinant DNA reagent (plasmid)pcDNA31.-TRMT1-FLAG-N-termThis paperFu Lab plasmid, mammalian expression vector for N-terminal TRMT1 fragment fused to FLAG
Recombinant DNA reagent (plasmid)pcDNA31.-TRMT1-FLAG-C-termThis paperFu Lab plasmid, mammalian expression vector for C-terminal TRMT1 fragment fused to FLAG
Recombinant DNA reagent (plasmid)pLenti-CMV-GFP-BlastAddgeneAddgene #17445
Recombinant DNA reagent (plasmid)pLenti-CMV-TRMT1-FLAGThis paperFu Lab plasmid, lentiviral expression vector for wild-type TRMT1 fused to FLAG
Recombinant DNA reagent (plasmid)pLenti-CMV-TRMT1-FLAG-Q530NThis paperFu Lab plasmid, lentiviral expression vector for TRMT1-Q530N fused to FLAG
Recombinant DNA reagent (plasmid)psPAX2AddgeneAddgene # 12260
Recombinant DNA reagent (plasmid)pMD2.GAddgeneAddgene #12259
OtherMagSTREP ‘type3’ XT beads, 5% suspensionIBA Lifesciences2-4090-002For protein purification
OtherDYKDDDDK-Tag Monoclonal Antibody Magnetic MicrobeadSyd LabsPA004830For protein purification
Antibodyanti-TRMT1 aa 201–229 (mouse monoclonal)Santa Cruz BiotechnologiesG3, sc-373687Western blot (1:1,000)
Antibodyanti-TRMT1 aa 609–659 (rabbit polyclonal)BethylA304-205AWestern blot (1:500)
AntibodyIBA LifeSciences StrepMAB-Classic (mouse monoclonal)Fisher ScientificNC9261069Western blot (1:1000)
AntibodyANTI-FLAG M2 (Mouse monoclonal)SigmaF3165Western blot (1:5000)
Antibodyanti-SARS-CoV-2 nucleoprotein N protein (Rabbit polyclonal)Sino Biological40068-RP01Western blot (1:1000)
Antibodyanti-actin C4 (Mouse monoclonal)EMD MilliporeMAB1501Western blot (1:1,000)
AntibodyIRDye 800CW anti-mouse IgG (goat polyclonal)Fisher Scientific925–32210Western blot secondary (1:10,000)
AntibodyIRDye 680RD anti-Mouse IgG (Goat polyclonal)Li-COR925–68070Western blot secondary (1:10,000)
OtherOdyssey Imager instrumentLi-CorCLxFor imaging infrared dye immunoblots.
Software, algorithmImage StudioLi-CorVersion 5.2
Software, algorithmFiji (Fiji is just ImageJ)Schindelin et al., 2012Release 2.15.1
Recombinant DNA reagent (plasmid)RRL.sin.cPPT.SFFV/
Ace2.WPRE (MT136)
Rebendenne et al., 2021Addgene 145842
Antibodyanti-ACE2 Antibody (Goat polyclonal)R&D systemsAF933Western blot (1:200)
Sequence-based reagentSARS_ForThis paperQRT-PCRACAGGTACGTTAATAGTTAATAGCGT
Sequence-based reagentSARS_RevThis paperQRT-PCRATATTGCAGCAGTACGCACACA
Sequence-based reagentGAPDH_ForThis paperQRT-PCRGCTCACCGGCATGGCCTTTCGCGT
Sequence-based reagentGAPDH_RevThis paperQRT-PCRTGGAGGAGTGGGTGTCGCTGTTGA

Additional files

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kejia Zhang
  2. Patrick Eldin
  3. Jessica H Ciesla
  4. Laurence Briant
  5. Jenna M Lentini
  6. Jillian Ramos
  7. Justin Cobb
  8. Joshua Munger
  9. Dragony Fu
(2024)
Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease
eLife 12:RP90316.
https://doi.org/10.7554/eLife.90316.3